发布求助
文献互助 智能选刊 最新文献

American journal of therapeutics最新文献

筛选
英文 中文
Transplanted Kidney Failure and Bleeding Caused by Combination of Tacrolimus, Paxlovid, and Dalteparin. 他克莫司、Paxlovid 和 Dalteparin 联合用药导致移植肾衰竭和出血。
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-10-22 DOI: 10.1097/MJT.0000000000001764
Xin-Liang Yang, Ye-Jun Chen, Wei Ou, Xiao-Hua Xie
{"title":"Transplanted Kidney Failure and Bleeding Caused by Combination of Tacrolimus, Paxlovid, and Dalteparin.","authors":"Xin-Liang Yang, Ye-Jun Chen, Wei Ou, Xiao-Hua Xie","doi":"10.1097/MJT.0000000000001764","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001764","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Characteristics and Prognosis of 39 Cases of Retinoblastoma With Optic Nerve Stump Involvement. 39例视神经残端受累视网膜母细胞瘤的临床特征和预后
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-10-18 DOI: 10.1097/MJT.0000000000001794
Yi-Zhuo Wang, Hui-Min Hu, Yi Zhang, Ji-Tong Shi, Jian-Min Ma, Wei-Ling Zhang, Hua-Li Gu, Yan Zhou, Dong-Sheng Huang
{"title":"Clinical Characteristics and Prognosis of 39 Cases of Retinoblastoma With Optic Nerve Stump Involvement.","authors":"Yi-Zhuo Wang, Hui-Min Hu, Yi Zhang, Ji-Tong Shi, Jian-Min Ma, Wei-Ling Zhang, Hua-Li Gu, Yan Zhou, Dong-Sheng Huang","doi":"10.1097/MJT.0000000000001794","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001794","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Ibrutinib as Monotherapy or Combination Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): A Systematic Review and Meta-analysis. 伊布替尼作为单药或联合疗法治疗复发/难治性弥漫大B细胞淋巴瘤（R/R DLBCL）的疗效和安全性：系统综述与元分析》。
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-10-16 DOI: 10.1097/MJT.0000000000001831
Yin Li, Chunfan Li, Kebing Lv, Shixuan Wang, Fei Li
{"title":"Efficacy and Safety of Ibrutinib as Monotherapy or Combination Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): A Systematic Review and Meta-analysis.","authors":"Yin Li, Chunfan Li, Kebing Lv, Shixuan Wang, Fei Li","doi":"10.1097/MJT.0000000000001831","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001831","url":null,"abstract":"<p><strong>Background: </strong>Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease group. Ibrutinib's monotherapy or combination therapy is effective in relapsed/refractory (R/R) DLBCL. However, the treatment response in R/R DLBCL varies from 15% to 90% with different regimens, and the tolerance remains controversial.</p><p><strong>Areas of uncertainty: </strong>The efficacy and safety of ibrutinib monotherapy or combination therapy in patients with R/R DLBCL remain uncertain.</p><p><strong>Data sources: </strong>The PubMed, CBM, MEDLINE, Cochrane Library, and Embase databases were searched from their inception to July 2021.</p><p><strong>Therapeutic advances: </strong>The total complete remission rate (CRR) and overall response rate in R/R DLBCL patients treated with ibrutinib were 26% and 49%, respectively. The CRR of ibrutinib combination therapy was significantly higher than the ibrutinib monotherapy (45% vs. 19%). Moreover, the CRR of patients was 40% in double expressing lymphoma, 35% in central nervous system lymphoma, and 33% in nongerminal center B-cell-like (non-GCB) DLBCL, which was higher than the 8% in those with the GCB subtype. The pooled median PFS and overall survival were 5.57 and 10.17 months, respectively. GCB-DLBCL had the worst overall survival (5.1 months). Nevertheless, we found that combination regimens had no survival advantage compared with monotherapy (P > 0.05), indicating that combination therapy was only a transitional treatment and bridge for chimeric antigen receptor T cells or other treatments. Moreover, 12% of patients on ibrutinib combination therapy had ≥grade 3 adverse events compared with 9% on ibrutinib monotherapy.</p><p><strong>Conclusions: </strong>Ibrutinib monotherapy or combination therapy was safe and effective in treating R/R DLBCL with tolerable adverse reactions.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mesalazine-Associated Agranulocytosis. 美沙拉嗪相关粒细胞减少症
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-10-16 DOI: 10.1097/MJT.0000000000001832
You-Jiao Chen, Dan-Ni Luo, Zi-Meng Wan, Feng Chen
{"title":"Mesalazine-Associated Agranulocytosis.","authors":"You-Jiao Chen, Dan-Ni Luo, Zi-Meng Wan, Feng Chen","doi":"10.1097/MJT.0000000000001832","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001832","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effect of a Prior Malignancy on the Prognosis of Patients With Extranodal NK/T-Cell Lymphoma. 曾患恶性肿瘤对结节外NK/T细胞淋巴瘤患者预后的影响
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-10-15 DOI: 10.1097/MJT.0000000000001784
Pu Xiang, Ji-Heng Wang, Lina Liu
{"title":"The Effect of a Prior Malignancy on the Prognosis of Patients With Extranodal NK/T-Cell Lymphoma.","authors":"Pu Xiang, Ji-Heng Wang, Lina Liu","doi":"10.1097/MJT.0000000000001784","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001784","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trastuzumab Deruxtecan in HER2-Positive Breast Cancer with HER2 Loss After Dual-Target Adjuvant Therapy: A Case Report. 曲妥珠单抗地屈孕酮治疗双靶向辅助治疗后 HER2 缺失的 HER2 阳性乳腺癌：病例报告。
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-10-11 DOI: 10.1097/MJT.0000000000001795
Wei Ouyang, Yixin Liu, Jun Cao, Jinghua Chen
{"title":"Trastuzumab Deruxtecan in HER2-Positive Breast Cancer with HER2 Loss After Dual-Target Adjuvant Therapy: A Case Report.","authors":"Wei Ouyang, Yixin Liu, Jun Cao, Jinghua Chen","doi":"10.1097/MJT.0000000000001795","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001795","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eosinophil-Related Disorders With Myelitis as the Predominant Clinical Manifestation: A Case Report. 以脊髓炎为主要临床表现的嗜酸性粒细胞相关疾病：病例报告。
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-09-27 DOI: 10.1097/MJT.0000000000001789
Min-Hui Shen, Ji-Hong Jiang, Cong-Ying Xu
{"title":"Eosinophil-Related Disorders With Myelitis as the Predominant Clinical Manifestation: A Case Report.","authors":"Min-Hui Shen, Ji-Hong Jiang, Cong-Ying Xu","doi":"10.1097/MJT.0000000000001789","DOIUrl":"10.1097/MJT.0000000000001789","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142085881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dexmedetomidine Attenuates Hemodynamic and Proinflammatory Responses During Craniotomy for Traumatic Brain Injury. 右美托咪定可减轻创伤性脑损伤开颅手术过程中的血流动力学反应和促炎症反应。
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-09-24 DOI: 10.1097/MJT.0000000000001788
Li-Ying Li, Yan-Xin Cheng, Guang-Ping Zhao, Jun-De Hou, Xiao-Wei Wang, Shu-Rui Li, Sen-Ming Zhao, Yong-Xue Chen
{"title":"Dexmedetomidine Attenuates Hemodynamic and Proinflammatory Responses During Craniotomy for Traumatic Brain Injury.","authors":"Li-Ying Li, Yan-Xin Cheng, Guang-Ping Zhao, Jun-De Hou, Xiao-Wei Wang, Shu-Rui Li, Sen-Ming Zhao, Yong-Xue Chen","doi":"10.1097/MJT.0000000000001788","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001788","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Efficacy and Safety of Resmetirom Versus Semaglutide in Treating MASH and MASLD: A Network Meta-Analysis. 瑞美曲隆与赛马鲁肽治疗 MASH 和 MASLD 的疗效和安全性比较：一项网络 Meta 分析。
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-09-19 DOI: 10.1097/MJT.0000000000001808
Hazem Ayesh
{"title":"Comparative Efficacy and Safety of Resmetirom Versus Semaglutide in Treating MASH and MASLD: A Network Meta-Analysis.","authors":"Hazem Ayesh","doi":"10.1097/MJT.0000000000001808","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001808","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of FGF21 Versus Semaglutide in the Management of Metabolic-Associated Steatotic Liver Disease: A Network Meta-analysis. FGF21 与塞马鲁肽治疗代谢相关性脂肪肝的有效性和安全性：网络 Meta 分析
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-09-19 DOI: 10.1097/MJT.0000000000001814
Hazem Ayesh, Omolola B Olajide
{"title":"Efficacy and Safety of FGF21 Versus Semaglutide in the Management of Metabolic-Associated Steatotic Liver Disease: A Network Meta-analysis.","authors":"Hazem Ayesh, Omolola B Olajide","doi":"10.1097/MJT.0000000000001814","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001814","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信